Daiichi Sankyo’s Prasugrel Granted U.S. FDA Priority Review
This article was originally published in PharmAsia News
Executive Summary
On Feb. 21, Japan's Daiichi Sankyo reported progress in drug research and development at a briefing in Tokyo with its antiplatelet agent prasugrel granted a priority review from U.S. FDA. The company anticipates approval as early as June 2008. Daiichi Sankyo also applied for European Medicines Agency approval. Other products to enter Phase III trials in 2008 include anticoagulant (factor Xa inhibitor) DU-176b, type II diabetes drug rivoglitazone, hypertension drug Olmesartan franchise CS-8635 and anti-RANKL antibody Denosumab. (Click for more-Japanese language